ABBV34.SA
AbbVie Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 4,
"returned": 4,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "206301c2-ad73-4741-8e00-db308e13bb68",
"title": "Earnings call: AbbVie projects robust growth and diversified pipeline By Investing.com",
"description": "Earnings call: AbbVie projects robust growth and diversified pipeline",
"keywords": "",
"snippet": "In a recent earnings call, AbbVie Inc . (NYSE: ) executives outlined a positive outlook for the company's growth, emphasizing the strong performance of its infl...",
"url": "https://www.investing.com/news/stock-market-news/earnings-call-abbvie-projects-robust-growth-and-diversified-pipeline-93CH-3443118",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPEB2404R_L.jpg",
"language": "en",
"published_at": "2024-05-15T23:22:20.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBV34.SA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 37.754795,
"sentiment_score": 0.393825,
"highlights": [
{
"highlight": "In a recent earnings call, <em>AbbVie</em> <em>Inc</em> . (NYSE: ) executives outlined a positive outlook for the company's growth, emphasizing the strong performance of its inflammatory and immunology drugs SKYRIZI and RINVOQ.",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> is expanding its oncology portfolio with an ADC platform and anticipates entering Phase III trials in colon cancer with ABBV-400.\n\nThe company is optimistic about the growth of its neurology drug, emra, and expects continued market share capture with VRAYLAR in bipolar disorder and adjunctive MDD.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Company Outlook\n\nExecutives expect robust growth for <em>AbbVie</em>, despite anticipated impacts from Part D benefit changes in 2025.\n\nThe company's strategic focus remains on deepening its core in therapeutic areas such as immunology and oncology.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> is committed to deleveraging to achieve a net leverage of 2x in the next 2 to 3 years but has the capacity for smaller-sized acquisitions.",
"sentiment": 0.1406,
"highlighted_in": "main_text"
},
{
"highlight": "With a diversified pipeline and a focus on core therapeutic areas, <em>AbbVie</em> appears poised for continued success in the pharmaceutical industry.\n\nInvestingPro Insights\n\n<em>AbbVie</em> <em>Inc</em>.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nFor more detailed analysis and additional \"InvestingPro Tips\" on <em>AbbVie</em>, including the 17 analysts who have revised their earnings upwards for the upcoming period, visit https://www.investing.com/pro/ABBV.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "There are 12 more \"InvestingPro Tips\" available on InvestingPro that can provide further depth to your investment research on <em>AbbVie</em>.\n\nFull transcript - <em>AbbVie</em> <em>Inc</em> (ABBV) Q1 2023:\n\nOperator:\n\nGeoffrey Meacham: With me on stage is CEO, Rob Michael, currently President and COO, I guess, but soon to be.\n\nRobert Michael: Soon to be, yes.",
"sentiment": 0.3071,
"highlighted_in": "main_text"
},
{
"highlight": "Earnings call: <em>AbbVie</em> projects robust growth and diversified pipeline By Investing.com",
"sentiment": 0.6124,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "1403c340-5514-4922-a20b-255820a10c88",
"title": "AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript",
"description": "AbbVie, Inc. (NYSE:NYSE:ABBV) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ETCompany ParticipantsRobert Michael - CEORoopal Thakkar -...",
"keywords": "",
"snippet": "AbbVie, Inc. (NYSE:ABBV) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ET\n\nCompany Participants\n\nRobert Michael - CEO\n\nRoopal Thakkar - SVP, ...",
"url": "https://seekingalpha.com/article/4693650-abbvie-inc-abbv-bank-of-america-health-care-conference-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-05-15T21:50:05.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBV34.SA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 79.415405,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "<em>AbbVie</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em>, <em>Inc</em>. (ABBV) Bank of America Health Care Conference Call Transcript",
"sentiment": 0.4939,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "618f8aa3-7672-498f-9ed2-77c0b0e9a7e7",
"title": "2 Fortune 100 Best Co's To Work For Are Also Good To Own",
"description": "Discover the top dividend-paying stocks from Fortune's BCTWF list, offering impressive yields and potential gains in 2024. Click here for the list.",
"keywords": "",
"snippet": "Ksenia Raykova/iStock via Getty Images\n\nForeword\n\nThis article is based on the April 4, 2024, \"Fortune*100 Best Companies To Work For\" article by Chloe Berger a...",
"url": "https://seekingalpha.com/article/4693591-2-fortune-100-best-cos-to-work-for-are-also-good-to-own",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1187807387/image_1187807387.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-05-15T19:37:00.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBV34.SA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.84931,
"sentiment_score": 0.1648,
"highlights": [
{
"highlight": "<em>AbbVie</em> <em>Inc</em> (ABBV) was projected to net $154.39, based on the median of estimates from 25 analysts, plus dividends, less broker fees. The Beta number showed this estimate subject to risk/volatility 39% less than the market as a whole.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Down the line, fifth place was secured by the healthcare representative, <em>AbbVie</em> <em>Inc</em> [5]. Finally, in eighth and ninth places were two technology sector members, HP Inc [8], and Cisco Systems Inc [9] which were followed by the lone communication services member, Comcast Corp to complete the top ten F100-Besties of 2024 dividend pack for May.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Five higher-priced F100-Besties for 2024 Dividend Dogs as of May 13 were: Dow Inc; Camden Property Trust; Teleperformance SE; <em>AbbVie</em> <em>Inc</em>; Allianz SE, whose prices ranged from $59.36 to $284.04.\n\nThe distinction between five low-priced dividend dogs and the general field of ten reflected Michael B. O'Higgins' \"basic method\" for beating the Dow.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "cec42216-dbba-49c9-9a2c-94d5aa25187e",
"title": "Sarah Ketterer's Strategic Moves in Q1 2024: A Focus on UBS Group AG",
"description": "Insights into Causeway Capital Management's Latest 13F Filings\n\nSarah Ketterer (Trades, Portfolio), CEO of Causeway Capital Management, has made significant adj",
"keywords": "GuruFocus, Article, News, GuruFocus Research, CP, RYAAY, BBD, GOOG, DIS, ORCL, TRMB, TME, PBR.A, UBS, AVTR, ABBV",
"snippet": "Insights into Causeway Capital Management's Latest 13F Filings\n\nSarah Ketterer (Trades, Portfolio), CEO of Causeway Capital Management, has made significant adj...",
"url": "https://www.gurufocus.com/news/2438744/sarah-ketterers-strategic-moves-in-q1-2024-a-focus-on-ubs-group-ag",
"image_url": "https://s3.amazonaws.com/gurufocus_userupload/1790804498931937280.png",
"language": "en",
"published_at": "2024-05-15T19:01:18.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABBV34.SA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.690243,
"sentiment_score": 0.5267,
"highlights": [
{
"highlight": "<em>AbbVie</em> <em>Inc</em> (ABBV, Financial), reduced by 189,253 shares, resulting in a -46.98% reduction in shares and a -0.75% impact on the portfolio. The stock traded at an average price of $172.34 during the quarter and has returned -6.55% over the past 3 months and 7.50% year-to-date.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "ABBV34.SA",
"total_documents": 4,
"sentiment_avg": 0.33306875452399254
}
]
}
Other details
Exchange
- The B3 S.A. - Brasil, Bolsa, Balcão
- equity
- Healthcare
- br